News | June 15, 2021
JB Chemicals PAT jumps by 101% to Rs101 Cr
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
India is expecting to manufacture 30-35 crore COVID-19 vaccines between July - August 2021
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The study was conducted in patients with mild to moderate COVID-19
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
For undertaking production, the company has been provided a Rs. 65 crore grant by the centre and Rs. 94 crore from the government of Maharashtra
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
Researchers observed that a form of vitamin D, known as 25-hydroxyvitamin D3 (Calcifediol), was absorbed faster and better than the same dose of vitamin D.
Subscribe To Our Newsletter & Stay Updated
